Atara Biotherapeutics (ATRA) Net Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Net Margin came in at 767.3% in Q2 2026, down 78088.0% on a YoY basis from N/an in Q2 2025, and up 4.48% quarter-over-quarter from 803.29% in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) Net Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported Net Margin for 6 consecutive years, with 767.3% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 78088.0% year-over-year to 767.3%; the trailing twelve-month figure through Jun 2026 stood at 379.56% (down 38263.0% YoY), and the FY2025 full-year result was 21.42%, up 8765.0% from the prior year.
- Net Margin improved to 767.3% in Q2 2026 per ATRA's latest filing, from 803.29% in the prior quarter.
- Across five years, Net Margin topped out at 38.73% in Q1 2025 and bottomed at 30111.69% in Q4 2022.
- Historically, Net Margin has averaged 2997.09% across 5 years, with a median of 704.28% in 2025.
- The sharpest annual moves came in 2022 and 2023: Net Margin slumped 2887223 bps in 2022, then soared 2868415 bps in 2023.
- Over 5 years, Net Margin stood at 30111.69% in 2022, then surged by 95 bps to 1427.54% in 2023, then surged by 97 bps to 38.75% in 2024, then tumbled by 1555 bps to 641.25% in 2025, then dropped by 20 bps to 767.3% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 767.3%, 803.29%, and 641.25% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -25,036.33% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 2.88% |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | -767.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -767.30% |
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -641.25% |
| Sep 30, 2025 | -124.62% |
| Jun 30, 2025 | 13.58% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.75% |
| Sep 30, 2024 | -54.51% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -116.07% |
| Dec 31, 2023 | -1,427.54% |
| Sep 30, 2023 | -3,264.59% |
| Jun 30, 2023 | -7,430.30% |
| Mar 31, 2023 | -6,098.78% |
| Dec 31, 2022 | -30,111.69% |
| Sep 30, 2022 | -1,885.87% |
| Jun 30, 2022 | 35.80% |
| Mar 31, 2022 | -1,204.61% |
| Dec 31, 2021 | -1,239.47% |
| Sep 30, 2021 | -1,576.61% |